

1 **Persistent immune abnormalities discriminate post-COVID syndrome from**
2 **convalescence**

3 Julia Sbierski-Kind^{1,2*}, Stephan Schlickeiser^{3,4}, Svenja Feldmann⁵, Veronica Ober⁵,
4 Eva Grüner⁵, Claire Pleimelding⁵, Leonard Gilberg⁵, Isabel Brand⁶, Nikolas Weigl⁷,
5 Mohamed I. M. Ahmed^{6,8}, Gerardo Ibarra^{2,9}, Michael Ruzicka^{9,10}, Christopher
6 Benesch^{9,11}, Anna Pernpruner^{9,11}, Elisabeth Valdinoci^{9,11}, Michael Hoelscher^{6,8},
7 Kristina Adorjan^{9,12}, Hans Christian Stubbe^{6,9,11}, Michael Pritsch^{6,8}, Ulrich Seybold⁵,
8 Johannes Bogner^{5,6}, Julia Roider^{5,6*} on behalf of the Post Covid Care and KoCo19
9 study groups

10

11

12 **Affiliations:**

13 1. Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität
14 München, Munich, Germany.

15 2. Department of Internal Medicine IV, Division of Diabetology, Endocrinology and
16 Nephrology, University Hospital, Eberhard-Karls-Universität Tübingen, Tübingen,
17 Germany.

18 3. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin
19 and Humboldt- Universität zu Berlin, Institute of Medical Immunology,
20 Augustenburger Platz 1, 13353 Berlin, Germany.

21 4. Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center
22 for Regenerative Therapies (BCRT), Charitéplatz 1, 10117 Berlin, Germany.

23 5. Department of Infectious Diseases, Department of Medicine IV, University
24 Hospital, Ludwig-Maximilians-Universität München, Munich, Germany

25 6. German Center for Infection Research (DZIF), Partner Site Munich, Munich,
26 Germany.

27 7. Department of Medicine IV, Division of Clinical Pharmacology, University Hospital,
28 Ludwig-Maximilians-Universität München, Munich, Germany

29 8. Division of Infectious Diseases and Tropical Medicine, University Hospital,
30 Ludwig-Maximilians-Universität München, Munich, Germany

31 9. COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, Ludwig-
32 Maximilians-Universität München, Munich, Germany.

33 10. Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität
34 München, Munich, Germany.

35 11. Department of Medicine II, University Hospital, Ludwig-Maximilians-Universität
36 München, Munich, Germany

37 12. Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-
38 Maximilians-Universität München, Munich, Germany.

39

40 **Corresponding authors. Email:**

41 Julia.Roider@med.uni-muenchen.de, Julia.Sbierski-Kind@med.uni-tuebingen.de

42 Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität
43 München, Munich, Germany

medRxiv preprint doi: <https://doi.org/10.1101/2023.05.02.23289345>; this version posted May 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

44 **Abstract**

45 Innate lymphoid cells (ILCs) are key organizers of tissue immune responses and
46 regulate tissue development, repair, and pathology. Persistent clinical sequelae
47 beyond 12 weeks following acute COVID-19 disease, named post-COVID syndrome
48 (PCS), are increasingly recognized in convalescent individuals. ILCs have been
49 associated with the severity of COVID-19 symptoms but their role in the
50 development of PCS remains poorly defined. Here we used multiparametric immune
51 phenotyping, finding expanded circulating ILC precursors (ILCPs) and concurrent
52 decreased group 2 innate lymphoid cells (ILC2s) in PCS patients compared to well-
53 matched convalescent control groups at > 3 months after infection. Patients with
54 PCS showed elevated expression of chemokines and cytokines associated with
55 trafficking of immune cells (CCL19/MIP-3b, FLT3-ligand), endothelial inflammation
56 and repair (CXCL1, EGF, RANTES, IL1RA, PDGF-AA). These results define
57 immunological parameters associated with PCS and might help find biomarkers and
58 disease-relevant therapeutic strategies.

59

60 **Keywords**

61 Innate lymphoid cells, COVID-19, Post-COVID-19-Syndrome, immune activation,
62 tissue immunology

63

64 **Abbreviations**

65 EFG: epidermal growth factor

66 FLT-3 Ligand: Fms-related tyrosine kinase 3 ligand

67 IF- γ : interferon γ

68 ILC: Innate lymphoid cells

69 ILCP: Innate lymphoid cell precursors

70 ILC2s: Group 2 innate lymphoid cells

71 IL: interleukin

- 72 IL1RA: interleukin-1 receptor antagonist
- 73 PBMCs: Peripheral blood mononuclear cells
- 74 PAIS: Post-acute infection syndromes (PAIS)
- 75 PC: Post-Covid
- 76 PCS: Post-COVID-Syndrome
- 77 PDGF-AA: platelet-derived growth factor A
- 78 SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
- 79 TNF: tumor necrosis factor
- 80 t-SNE: t-distributed stochastic neighbor embedding
- 81 VEGF: vascular endothelial growth factor
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94

95 Introduction

96 Viral infections can result in chronic symptoms that persist in previously healthy
97 convalescent individuals across a wide range of viral families, including Ebola virus,
98 influenza, Epstein-Barr virus, and dengue fever^{1,2}. The main symptoms are exertion
99 intolerance, fatigue, neurocognitive and sensory impairment, sleep disturbances, flu-
100 like symptoms, myalgia/arthralgia, and a plethora of nonspecific symptoms³. These
101 post-acute infection syndromes (PAIS) are associated with autoimmunity and
102 endothelial dysfunction, affecting both large and small vessels^{3,4}; however, risk
103 factors and the underlying pathophysiology remain largely unknown.

104 The COVID-19 pandemic, caused by infection with severe acute respiratory
105 syndrome coronavirus 2 (SARS-CoV-2), has led to an increasing prevalence of
106 convalescent patients with prolonged and persistent sequelae following acute SARS-
107 CoV-2 infection- known as 'long COVID' or 'post-COVID syndrome'⁵. The estimated
108 prevalence of PCS ranges from 5-50%⁶, thus presenting an enormous global health
109 burden, and can affect both patients with mild or severe forms of acute COVID-19
110 disease⁷. Clinical symptoms include fatigue, malaise, depression, cognitive
111 impairment, persistent cough, dyspnoea, palpitations, and headaches⁸. While the
112 acute phase of COVID-19 has been extensively studied, providing health care
113 professionals with efficient treatment options, the pathogenesis of PCS remains
114 unclear, with current hypotheses including autoimmunity, latent virus reactivation,
115 tissue, and endothelial damage⁹.

116 The extreme respiratory distress in patients with acute COVID-19 is mediated
117 primarily by immunopathology and systemic inflammation. Pathological immune
118 signatures suggestive of T cell exhaustion, delayed bystander CD8⁺ T cell activation,
119 and higher plasma GM-CSF and CXCL10 levels are associated with severity of the
120 disease^{10,11,12}. Survivors of severe COVID-19 show persistent immune
121 abnormalities, including elevated levels of pro-inflammatory cytokines¹³. In addition
122 to systemic inflammation, SARS-CoV-2 infects endothelial cells, causing virus-
123 mediated apoptosis and consecutive endotheliitis and, thus, may promote
124 endothelial damage and increased recruitment of activated immune cells into the
125 endothelium and surrounding tissue¹⁴.

126

127 Dysregulated respiratory CD8⁺ T cell responses may contribute to impaired tissue
128 conditions and development of pulmonary sequelae¹⁵. Recent work identified
129 persistent immunological dysfunction in patients with post-acute sequelae of COVID-
130 19, including highly activated innate immune cells and marked differences in specific
131 circulating myeloid and lymphocyte populations^{16,17}.

132 Innate lymphoid cells (ILCs) are tissue-resident effector immune cells with crucial
133 roles in normal tissue development and remodeling^{18,19}. These cells also participate
134 in both protective and pathologic immune responses during lung tissue
135 perturbation^{20,21}. Several studies detected a reduction in total circulating ILCs in
136 severe COVID-19 patients, while relative group 2 innate lymphoid cells (ILC2) levels,
137 particularly NKGD⁺ ILC2s, were increased^{22,23}. Although ILCs appear central to lung
138 infection and repair, their role in PCS remains critically unexplored.

139 Here we used multicolor flow cytometry and multiplex cytokine assays on plasma
140 from (1) healthy, uninfected controls (n=32, 'HC'); (2) previously SARS-CoV-2-
141 infected individuals in the convalescent phase without persistent symptoms (n=32,
142 convalescent controls, 'CC'); and (3) individuals with persistent symptoms following
143 acute COVID-19 (n=27, post-COVID, 'PC') to identify specific immunological
144 alterations, including ILCs, in PCS. Among the CC and PC groups, most participants
145 were non-hospitalized during acute SARS-CoV-2 infection and CC and PC
146 individuals had persistent symptoms for more than 12 weeks from the initial infection.
147 We found expanded circulating ILC precursors (ILCPs) in PC individuals while ILC2s
148 were decreased. Patients with persistent symptoms also displayed elevated pro-
149 inflammatory cytokines (IL-8, IL-6), chemokines associated with trafficking of
150 immune cells (CCL19/MIP-3b, FLT3-Ligand), and endothelial inflammation and
151 repair (CXCL1, EGF, RANTES, PDGF-AA).

152

153 **Results and Discussion**

154

155 **Clinical characteristics of study participants**

156 Patients, enrolled in the Post-COVID-Care study at the LMU University Hospital
157 Munich, presented with persistent symptoms for more than 12 weeks following acute
158 SARS-CoV-2 infection (PC group; n=27) and were compared to convalescent
159 patients without persistent symptoms (CC group; n=32) and healthy controls (HC

160 group; n=32), enrolled in the KoCo19-index study (**Fig. 1A**). Clinical demographics of
161 both study cohorts are reported in **Table 1**. The PCS, convalescent, and healthy
162 control groups were well-matched in sex (67% female PC; 56% female CC; 53%
163 female HC; Chi-square: 1.185, d.f. = 2), age (mean 37.15 years old PC; mean 36.09
164 years old CC; mean 35.91 years old HC; Kruskal-Wallis test $p=0.9276$), and BMI
165 (mean BMI PC group 24.0kg/m^2 ; mean BMI CC group 23.4kg/m^2 ; mean BMI HC
166 group 25.2kg/m^2 ; Kruskal-Wallis test $p=0.3315$) (**Fig. 1B and Table 1**). Only 2
167 patients with COVID-19 sequelae were hospitalized during acute infection, whereas
168 none of the convalescent study participants were hospitalized (**Fig. 1C**), reflecting
169 that some patients experience long-term health-consequences after acute COVID-
170 19, regardless of disease severity. For PC and CC groups, elapsed days since initial
171 SARS-CoV-2 infection were different in median times from acute disease (113 days
172 for PC group vs. 273 days for CC group; Mann-Whitney $p= <0.0001$) (**Fig. 1D**);
173 however, initial enrolment and collection of blood for immunophenotyping took place
174 more than 3 months after onset of COVID-19 and none of the convalescent
175 participants reported persistent symptoms after acute disease. Acute SARS-CoV-2
176 infections within the PC group occurred in the period when the Omicron BA.2
177 variants were dominant (between January and March 2022), whereas participants of
178 the convalescent group were confirmed to be infected with SARS-CoV-2 between
179 March and April 2020, when parental strains drove the majority of new cases. While
180 several risk factors, including comorbidities and virus variants, have been identified
181 for the development of PCS²⁴, clinical symptoms are similar for different SARS-CoV-
182 2 strains, with the exception of musculoskeletal pain, where chronic burden may be
183 lower for Omicron compared to Delta variants²⁵. Consistent with numerous previous
184 reports of PCS, the most common reported symptoms included constitutional
185 symptoms, such as fatigue (93%) and insomnia (41%), and neurological symptoms,
186 such as impaired alertness (74%), memory impairment (59%), and impaired speech
187 (56%). Cardiac symptoms, including palpitations (59%), chest pain (52%), and
188 reduced muscular strength (26%) were also a common complaint (**Fig. 1E**).

189

190 **Pro-inflammatory cytokines and growth factors are elevated in PCS**

191 In COVID-19 patients with severe disease, cytokine storm and uncontrolled
192 inflammatory responses, including endothelial inflammation and associated tissue
193 damage, are recognized as one of the driving immunopathological features that can

194 lead to death¹⁰. To uncover the immunological dysregulation in PCS, we quantified
195 46 molecular analytes in the plasma of patients from the CC and PC groups >3
196 months after acute SARS-CoV-2 infection using a multiplex cytokine assay and
197 compared them to healthy controls. Four key pro-inflammatory cytokines (interleukin-
198 8 (IL-8), IL-6, interleukin-1 receptor antagonist (IL-1Ra) and IL-1a) were elevated in
199 the PC group compared to the CC and HC groups (**Fig. 2A, Suppl. Fig. 1**), while no
200 difference was observed in transforming growth factor alpha (TGF- α), IL-7, IL-5, IL-4,
201 IL-13, IL-10, tumor necrosis factor (TNF α), interferon γ (IFN- γ) and IL-1 β (**Suppl.**
202 **Fig.1**). IL-8 has been previously associated with a prothrombotic neutrophil
203 phenotype in severe COVID-19 and blocking IL-8 signaling reduced SARS-CoV-2
204 spike protein-induced, human ACE2-dependent pulmonary microthrombosis in
205 mice²⁶. Surprisingly, levels of IL-8 and IL-6 were lower in CC compared to HCs,
206 whereas other pro-inflammatory cytokines were not different between these groups
207 (**Fig. 2A, Suppl. Fig. 1**). IL-1Ra was 2.16-fold higher in the PC group compared to
208 the HC group and 2.22-fold higher compared to the CC group; other pro-
209 inflammatory cytokines were only slightly increased (**Fig. 2A, Suppl. Fig.1**). Several
210 chemokines (RANTES, MIP3b, CXCL1) and growth factors (Fms-related tyrosine
211 kinase 3 ligand (FLT-3 Ligand), epidermal growth factor (EGF), vascular endothelial
212 growth factor (VEGF), platelet-derived growth factor A (PDGF-AA)), that could be
213 associated with trafficking of immune cells (MIP3b, FLT3-Ligand) and endothelial
214 inflammation (CXCL1, EGF, RANTES, PDGF-AA), CD40L and Granzyme B were
215 also elevated in PC participants compared to both CC and HC groups (**Fig. 2A,**
216 **Suppl. Fig.1**). Interestingly, Eotaxin (CCL11), monocyte chemoattractant protein 1
217 (MCP1), and IL-12p70 were decreased in PC patients compared to both
218 convalescent and healthy controls (**Suppl. Fig. 1**); some of these chemokines were
219 associated with severe cases of acute COVID-19²⁷. Importantly, programmed death-
220 ligand 1 (PD-L1) was increased in the persistent symptom group compared to both
221 convalescent and healthy control groups, consistent with previous reports,
222 highlighting the prognostic role of sPD-L1 in COVID-19 patients²⁸ (**Suppl. Fig.1**).
223 Although most plasma samples from the CC group were taken at month 8 after acute
224 COVID-19 infection while samples from the PC group were taken at month 4,
225 challenging direct comparison of persistent symptom and convalescent groups,
226 several studies have shown that pro-inflammatory cytokines remained significantly
227 elevated in PC patients at month 8 after acute infection¹⁷. Together, these data

228 suggest persistent immune abnormalities in patients suffering from post-acute
229 sequelae of COVID-19.

230

231 **Circulating ILCPs are elevated in PC patients with concurrent decrease in** 232 **ILC2s**

233 To investigate circulating ILC levels via flow cytometry in PCS, convalescent and
234 healthy controls, we used a well-established gating strategy²⁹ (**Suppl. Fig.2**). Lin⁻
235 CD127⁺ ILC subsets were defined as CD117⁻CRTH2⁻ ILC1s, CD117⁺ ILC
236 progenitors (ILCP)³⁰, and CRTH2⁺ ILC2s. We used CD56 as a marker of activated or
237 ILC3/NK cell-committed ILCP and CD45RA for naïve ILCP²⁹. Recent work
238 discovered CD45RA⁺ naïve-like ILCs, lacking proliferative activity, indicative of
239 cellular quiescence³¹. To visualize multiple dimensions in simple two dimensional
240 plots and compare flow cytometry data between groups, we used stochastic
241 neighbor embedding analysis (**Fig. 2 B, C**). We found increased expression of the
242 ILCP marker CD117 in PC compared to HC groups, while CRTH2 (marker for ILC2s)
243 was decreased in PC compared to both CC and HC groups (**Fig. 2B, C**). However,
244 the expression of proteins associated with ILC activation, CD56 (also defining NK
245 cells with intermediate or high expression levels) and HLA-DR, was not different
246 between groups (**Fig. 2B, C**). Next, we evaluated total numbers and frequencies of
247 circulating ILCs and NK cells in patients with persistent symptoms after COVID-19
248 infection as compared to convalescent patients and healthy controls. We did not
249 observe significant changes in total ILCs and subsequent ILC subsets (ILC2s, ILC1s,
250 ILCPs) in PC compared to CC and HC groups (**Suppl. Fig. 3A**). However, PC
251 patients had expanded levels of ILCPs with concurrent decreased ILC2 frequencies,
252 while ILC1 levels remained unchanged (**Fig. 2 D, E**). The role of ILC2s in viral-
253 induced lung pathogenesis remains controversial. Although increased levels of IL-18,
254 IL-13, and IL-6 have been reported along with accumulation of ILC2s during acute
255 COVID-19, increased circulating ILC2s in moderate but not severe COVID-19
256 patients were found in other studies³², consistent with their attrition by IFN- γ in type 1
257 (viral-induced) inflammation²⁰. Thus, ILC2s might have important roles in tissue
258 repair during viral-induced epithelial cell damage, perhaps through crosstalk with
259 other ILC subsets.

260 Recent work suggested that human ILCPs can interact with endothelial cells,
261 fostering the adhesion of other innate and adaptive immune cells by stimulating pro-

262 inflammatory cytokine expression of adhesion molecules. This activation occurs
263 through the tumor necrosis factor receptor- and RANK-dependent engagement of
264 *NF- κ B* pathway³³. Nevertheless, PC patients did not show significant changes in
265 CD45RA⁺ ILCPs, although CD56⁺ ILCPs were trending upwards, suggesting a
266 circulating ILCP expansion without overt altered activation (**Fig. 2E**). Surprisingly, the
267 expression of CD45RA was increased in both ILC1 and ILC2 subsets in the PC
268 group compared to HC (**Suppl. Fig. 3B**), suggesting the increase of a quiescent
269 local reservoir for the generation of differentiated ILCs³¹. Frequencies of HLA-DR⁺
270 ILC1s and the transcriptional expression of SLAMF1 within the ILC2 compartment
271 were similar between PC, CC, and HC groups (**Suppl. Fig. 3B**). We could not find
272 significant differences in NK cell frequencies between patients with PCS,
273 convalescent, and healthy controls (**Suppl. Fig. 3C**). Together, these data indicate
274 that ILCPs expand in patients with COVID-19 sequelae, without alteration of their
275 activation state.

276

277 **Concluding remarks**

278 Persistent sequelae following acute COVID-19 are increasingly recognized in
279 convalescent individuals. Our exploratory analyses identified immunological
280 differences in patients with PCS as compared to well-matched convalescent and HC
281 individuals at > 3 months post infection. We found significant changes in circulating
282 ILC subsets, including increased ILCPs and concurrent decreased ILC2 levels. In
283 addition, pro-inflammatory cytokines (IL-8, IL-6), chemokines associated with
284 trafficking of immune cells (CCL19/MIP-3b, FLT3-Ligand) and endothelial
285 inflammation and -repair (CXCL1, EGF, RANTES, PDGF-AA) were elevated in PC
286 participants. Although our work does not dissect how ILCPs or other activated innate
287 and adaptive immune cells, contribute mechanistically to endothelial dysfunction in
288 PCS, ILCP expansion along with elevated markers for endothelial inflammation in
289 PC supports their interaction with endothelial cells; thereby facilitating enhanced
290 inflammatory responses and endotheliitis in several organs. These findings may not
291 only be interesting for long-term sequelae of COVID-19, but also for other viral
292 infections that can result in PAIS in convalescent individuals. Further exploration of
293 immunological alterations in PCS may delineate mechanisms of ILC-endothelial cell
294 crosstalk and lead to disease-relevant targeted therapies.

295 **Data availability statement:** Further information and requests for resources and
296 reagents should be delivered to and will be fulfilled by the Lead Contact, Julia Roider
297 (Julia.Roider@med.uni-muenchen.de).

298 **Conflict of Interest:** The authors declare no commercial or financial conflicts of
299 interest.

300 **Ethics approval statement for human studies:** KoCo19 Shield: The study protocol
301 was reviewed and approved by the Institutional Review Board of the Medical Faculty
302 at Ludwig-Maximilians-University Munich, Germany under the project number 20-692
303 (vote of approval dated Sept. 21st, 2020) and 20-371 (vote of approval dated May
304 15th, 2020). Oral and written informed consent was obtained from all study subjects.
305 PCC: The study protocol was reviewed and approved by the Institutional Review
306 Board of the Medical Faculty at Ludwig-Maximilians-University Munich, Germany
307 under the project number 21-1165 (vote of approval dated Feb 15, 2021,
308 amendment approved Aug. 11, 2021). Oral and written informed consent was
309 obtained from all study subjects.

310 **Patient consent statement:** The patients/participants provided their written
311 informed consent to participate in this study.

312 **Author contributions:** Conception and design: JR and JSK. Cohort initiation, study
313 follow-up, data management and sample processing KoCo19 Shield: MH, MP, CP,
314 IB, LG, NW. Cohort initiation, study follow-up, data management and sample
315 processing PCC: HS, KA, US, JB, GI, EG, MR, CB, AP, EV. Acquisition of data:
316 JSK, SF, VO, HS, MA. Analysis and interpretation of data: JSK and SS. Writing of
317 the manuscript: JSK and JR. Critical reagents and manuscript editing: SF, VO, SS,
318 and MA. Funding acquisition: MH, HS, KA, JSK, JR.

319 **Acknowledgements:** We thank Renate Stirner and Gabriele Reiling for excellent
320 technical assistance. The Post-COVID^{LMU} research project is financially supported by
321 the Bavarian State Ministry for Health and Care and the Bavarian State Office for
322 Health and Food Safety (LGL). There is a close link to the nationwide research
323 project "Network University Medicine" (NUM), funded by the Federal Ministry of
324 Education and Research (BMBF) (funding code: 01KX2021) and the NUM-
325 associated research projects. JR is supported by the German Center for Infection
326 Research (DZIF) and Else Kröner-Fresenius-Stiftung (EKFS). JSK received funding

327 from the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft),
328 the German Diabetes Society (DDG, Deutsche Diabetes Gesellschaft), and
329 FoeFoLe, LMU Munich. JSK is also supported by the German Society of Internal
330 Medicine (DGIM, Deutsche Gesellschaft für Innere Medizin, Clinician Scientist
331 Program).

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352 **Figures and Figure Legends**

353 **Table 1: Clinical and demographic characteristics of study cohorts.** Data are
354 given as numbers (percentages). BMI, body mass index. Sex, age and BMI were
355 comparable between groups with an overall mean age of 36 years, 58% females and
356 BMI of 24.2kg/m².

357

358 **Figure 1: Clinical characteristics of study cohorts.**

359 (A) Overview of study cohorts and methods. The figure is partly created with
360 BioRender.com.

361

362 (B) Demographic characteristics for healthy controls with no prior SARS-CoV-2
363 infection (HC), convalescent SARS-CoV-2 participants without persisting symptoms
364 (CC) and convalescent SARS-CoV-2 participants with persisting symptoms (PC)
365 displayed as ring charts. Statistical significance is shown by capped lines as Chi-
366 square tests for 'Sex' and post-hoc comparisons for 'Age'. Characteristics are further
367 detailed in Table 1.

368 (C) Percentage of hospitalization during acute Covid infection for CC and PC
369 participants displayed as ring charts.

370 (D) Box plots showing days from first positive PCR test for CC and PC groups.
371 Central lines indicate group means; top and bottom lines indicate minimum and
372 maximum. Significance was assessed by Mann-Whitney-test.

373 (E) Prevalence of top 22 self-reported symptoms in PC participants ranked from
374 least prevalent (left) to most prevalent (right). Symptoms are colored according to
375 physiological systems. Gastrointestinal (GI), endocrine (Endo), pulmonary (Pulm),
376 constitutional (Const), neurological (Neuro), cardiac, and musculoskeletal (MSK).

377 ****p ≤ 0.0001. See also Table 1.

378

379 **Figure 2: Post-COVID participants show altered cytokine expression and levels
380 of innate lymphoid cells.**

381 (A) Multiplex assay quantification showing plasma levels of IL-8, IL-6, IL-1RA,
382 RANTES, FLT-3 Ligand and EGF in healthy controls with no prior SARS-CoV-2
383 infection (HC), convalescent SARS-CoV-2 participants without persisting symptoms
384 (CC), and convalescent SARS-CoV-2 participants with persisting symptoms (PC) at
385 3-10 months after acute COVID infection.

386

387 (B) High-dimensionality reduction analysis of innate lymphoid cells (ILCs, gated as
388 lymphocytes, singlets, and CD45⁺CD3⁻Lin⁻CD127⁺ cells as shown in Supplementary
389 Figure 3) from peripheral blood mononuclear cells (PBMCs) of HC, CC, and PC
390 groups. High-resolution group differences were visualized by calculating Cohen's D

391 for a given comparison across the t-SNE map. Residual plot showing differences
392 between maps. Phenotypes within red circles were confirmed to be statistically more
393 common in PC samples, and phenotypes within blue circles were less common in
394 PC samples. Analysis is based on flow cytometry data from 32 HC, 32, CC, and 27
395 PC samples.

396

397 (C) Relative expression intensities (combined HC, CC, and PC samples) of
398 parameters used in the t-SNE analysis.

399

400 (D and E) Representative flow cytometry plots (D) and quantification (D and E),
401 showing percent innate lymphoid cell populations in HC, CC, and PC groups at 3-10
402 months after acute COVID infection.

403 Bar graphs indicate mean (\pm SE), n=27-32 individuals per group, unpaired t-test (A,
404 D, E), * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$. See also Supplementary
405 Figure 1.

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425 **Materials and Methods**

426 **Study design**

427 **KoCo19-Shield sub study of the prospective Covid19 cohort Munich -Index** 428 **study (KoCo19-Index)**

429 To establish the KoCo19-index cohort, we recruited study subjects in whose
430 household at least one person had a PCR confirmed SARS-CoV-2 infection.
431 Recruitment was performed as previously described³⁴. In brief, individuals with PCR
432 confirmed SARS-CoV2 infection were contacted by the responsible official
433 authorities (City of Munich Health department) in May and June 2020. Individuals
434 who expressed interest in participating were enrolled in the KoCo19 index study. For
435 the KoCo19 – Shield sub study, at least one member of the participant’s household
436 (> 14 years old) also had to be willing to participate. The KoCo19-Shield sub study
437 comprised 177 PCR-positive individuals and 145 household members, enrolled
438 between September 29, 2020, and January 27, 2021. Personal data of the study
439 subjects was collected as previously described³⁵. In short, the mobile data collection
440 tool OpenDataKit (ODK) was used to capture data during study visits by field
441 workers on Android smartphones. Study subjects completed household
442 questionnaires as well as personal questionnaires using a web-based application.
443 Non-responders were reminded first by email, and in case of continued non-
444 response with a telephone reminder. Telephone interviews were offered to those
445 who felt unable to complete the questionnaires online. Clinical demographics of
446 study participants are reported in **Table 1**.

447 The study was approved by the Ethics Committee of the Medical Faculty at LMU
448 Munich (20–275 V) and the protocol is available online (www.koco19.de)³⁴. Informed
449 consent was obtained from all enrolled participants. The study is registered to the
450 German Clinical Trials Register (DRKS-ID: DRKS00022155).

451

452 **Post Covid Study**

453 Post-COVID-Care (PCC) study is an ongoing prospective single-center study
454 comprised of patients with persistent symptoms following acute COVID-19.
455 Participants with COVID-19 sequelae were recruited from the Post-COVID outpatient
456 clinic at the University Hospital LMU Munich. Samples were collected from
457 participants enrolled between April and July 2022. Inclusion criteria were age \geq 18

458 years; persistent symptoms > 12 weeks within 6 months following initial COVID-19
459 infection. Pre-specified exclusion criteria were other explanations for the symptom
460 onset or complete resolution of symptoms. All participants were scheduled for follow-
461 up for at least 6 months and up to 24 months if symptoms persisted. At baseline and
462 during the routine follow-up visits blood samples were obtained and each patient
463 completed progressive web app (PWA)-based questionnaires (LCARS-C, LMU
464 Munich). Patients who did not undergo any follow-up on site were asked to fill out the
465 follow-up surveys using the PWA-based questionnaire at home using a PC,
466 smartphone or tablet. Informed consent was obtained from all participants before
467 inclusion into the study. Clinical characteristics of study participants are reported in
468 **Table 1**. The study was approved by the Ethics Committee of the Medical Faculty at
469 LMU Munich (No. 21-1165) and registered to the German Clinical Trials Register
470 (DRKS-ID: DRKS00030974).

471

472 **Participant Surveys**

473 KoCo19 and PCC study participants completed a comprehensive suite of surveys,
474 combining validated patient-reported outcomes (PROs) with custom, purpose-
475 developed tools by the study team. Baseline demographic data collected from
476 surveys included gender, age, body mass index (BMI), race, and medical
477 comorbidities. Additionally, participants in the Long COVID and convalescent group
478 were asked to provide COVID-19 clinical data including date of symptom onset and
479 acute disease severity (non-hospitalized vs. hospitalized), SARS-CoV-2 polymerase
480 chain reaction (PCR) diagnostic testing results, and SARS-CoV-2 antibody testing
481 results. All participants were asked to report SARS-CoV-2 vaccination status
482 including date of vaccinations and vaccine brand.

483

484 **Blood sample processing**

485 Whole blood was collected in four potassium-EDTA-coated blood collection tubes
486 (Sarstedt) from participants at University Hospital, LMU, Munich, Germany.
487 Following blood draw, all participant samples were assigned unique study identifiers
488 and de-identified by research staff. Blood samples were processed the same day as
489 collection. Plasma samples were collected after centrifugation of whole blood at
490 450xg for 10 minutes at room temperature (RT). Plasma was then transferred to 1,8-
491 ml polyethylene Cryotube™ vials (ThermoFisher), aliquoted, and stored at -80°C. For

492 isolation of peripheral blood mononuclear cells (PBMCs), two tubes each of the
493 remaining whole blood sample were pooled and filled up to a total volume of 32.5 ml
494 with Hank's Balanced Salts Solution (Capricorn or Sigma). 13,5ml Histopaque®-
495 1077 (Sigma) were added at the bottom of each tube and samples were centrifuged
496 at 450xg for 30 minutes at RT without break. PBMC layer on top of the Histopaque®
497 layer was collected and washed twice in Hank's balanced salts solution. Isolated
498 cells were counted using a CASY cell counter and analyzer (Schärfe System GmbH)
499 before storage in liquid nitrogen at -180°C for cryopreservation.

500

501 **Flow cytometry**

502 Cryopreserved PBMCs were thawed in a 37°C water bath, pipetted into Iscove's
503 Modified Dulbecco's Medium (IMDM) supplemented with 10% FCS medium, and
504 washed by centrifugation. Three to six million cells per sample were incubated with
505 antibodies to surface antigens (Table S1) for 30 minutes at 4°C, washed with FACS
506 buffer (1XDPBS, 3% FCS, 0.05% NaN₃), fixed with 2% paraformaldehyde for 10
507 minutes, washed again with FACS buffer, and resuspended in FACS buffer. Flow
508 cytometry was performed on BD LSRFortessa X-20. Fluorochrome compensation
509 was performed with single-stained UltraComp eBeads (Invitrogen, Cat# 01-2222-42).
510 Samples were FSC-A/SSC-A gated to exclude debris, followed by FSC-H/FSC-A
511 gating to select single cells and Zombie NIR fixable or DAPI to exclude dead cells.
512 Innate lymphoid cells were identified as lineage negative (CD1a⁻, CD14⁻, CD19⁻,
513 CD34⁻, CD94⁻, CD123⁻, FcER1a⁻, TCRab⁻, TCRgd⁻, BDCA2⁻), CD45⁺, CD161⁺,
514 CD127⁺, as indicated. The full gating strategy is shown in Fig. S1 and was adapted
515 from previous work²⁹. Data were analyzed using FlowJo version 10.7 software
516 (TreeStar, USA) and compiled using Prism (GraphPad Software). T-distributed
517 stochastic neighbor embedding (t-SNE) visualization of flow cytometry data was
518 performed using Cytobank.

519

520 **Quantification of plasma cytokine levels**

521 The plasma levels of 46 molecular species were quantified using a Luminex platform
522 (Human Cytokine Discovery, R&D System, Minneapolis, MN) for the simultaneous
523 detection of the following molecules: G-CSF, PDGF-AA, EGF, PDGF-AB/BB, VEGF,
524 GM-CSF, FGF, GRZB, IL-1A, IL-1RA, IL-2, IL-27, IL-4, IL-6, IL-10, IL-13, TNF, IL-

525 17C, IL-11, IL-18, IL-23, IL-6RA, IL-19, IFN-B, IL-3, IL-5, IL-7, IL-12p70, IL-15, IL-33,
526 TGF-B, IFN-G, IL-1B, IL-17, IL-17E, CCL3, CCL11, CCL20, CXCL1, CXCL2,
527 CCL5, CCL2, CCL4, CCL19, CXCL1, CXCL10, PD-L1, FLT-3, TACI, FAS, LEPTIN
528 R, APRIL, OPN, BAFF, LEPTIN, BMP4, CD40 LIGAND, FAS LIGAND, BMP7,
529 BMP2, and TRAIL, according to the manufacturer's instruction

530 **Statistical analysis**

531 All data are expressed as means \pm standard error of the mean (SEM) unless
532 otherwise noted. Comparisons between two groups were analyzed by using
533 unpaired two-tailed Student's t-tests, and multiple comparisons were analyzed by
534 one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test
535 (Prism, GraphPad Software, La Jolla, CA), with * = $p < 0.05$, ** = $p < 0.01$, ***
536 = $p < 0.001$, **** = $p < 0.0001$. Each symbol reflects individuals for flow analysis or
537 plasma cytokine levels.

538

539 **Unsupervised data analysis.** Cytobank³⁶ was used for initial manual gating of
540 Lineage-negative cells and ILC subsets ILC1, ILC2, and ILCP, using the same gating
541 strategy as described above. FCS files were transformed with. Lineage-negative
542 cells were subjected to dimensionality reduction using Cytobank opt-SNE with
543 default hyperparameters and following embedding markers with normalized scales
544 Cytobank arcsinh transformation: CD117, CD127, CD161, CD45RA, CD56, CRTH2,
545 HLA-DR, and SLAMF1. All pre-gated events were used without prior downsampling
546 from 91 samples. In order to perform downstream statistical analyses in R
547 (<http://www.r-project.org/>) and visualize t-SNE maps across the 91 samples, events
548 within ILC subsets were exported from Cytobank as tab-separated values containing
549 compensated and transformed marker expression levels as well as t-SNE
550 coordinates and metacluster assignment. T-SNE plots were generated after
551 subsampling each sample to contain a maximum of 2500 events. High-resolution
552 group differences were visualized by calculating Cohen's D for a given comparison
553 across the t-SNE map. To this end, we generated adaptive 2D histograms using the
554 probability binning algorithm available through the R *flowFP* package³⁷. Dependent
555 on the total number of cells available, a single binning model was created on
556 collapsed data from all samples, by recursively splitting the events at the median
557 values along the two t-SNE dimensions. We chose a grid of 256 bins to have, on

558 average, at least eight cells per bin in each sample for statistical accuracy. Since
559 there was a significant difference between cellular frequency distributions between
560 the six measurement days, the batch effect was first regressed out by fitting a linear
561 model to each bin after applying the arcsine-square-root transformation for
562 proportions. The group-difference effect sizes were then calculated for each bin
563 using the `cohen.d` function of the *effsize* package. In order to get a smoothed
564 representation of the effect size map, adaptive binning was performed on a series of
565 rotated coordinates and per cell-averaged effect size values were used to color-
566 encode each cell throughout the t-SNE map. All analyses were performed using R
567 version 4.1.1, available free online at <https://www.r-project.org>.

568

569 **Post Covid Care group members**

570 Kristina Adorjan, Shahnaz C. Azad, Petra Bäumlner, Christopher Bensch, Johannes
571 Bogner, Svenja Anike Feldmann, Fides Heimkes, Gerardo Ibarra, Dominik Irrnich,
572 Anna-Lena Johlke, Stefan Kääh, Kathrin Kahnert, Eduard Kraft, Katrin Milger-
573 Kneidinger, Veronica Ober, Anna Pernpruner, Jan Rémi, Julia Roider, Michael
574 Ruzicka, Simone Sachenbacher, Florian Schöberl, Konstantin Stark, Andreas
575 Straube, Hans Christian Stubbe, Elisabeth Valdinoci, Martin Weigl, Nora Wunderlich.

576

577 **KoCo19 study group members**

578 Emad Alamoudi, Jared Anderson, Abhishek Bakuli, Marc Becker, Franziska
579 Bednarzki, Olimbek Bemirayev, Jessica Beyerl, Patrick Bitzer, Rebecca Boehnlein,
580 Friedrich Caroli, Lorenzo Contento, Alina Czwienzek, Flora Deák, Maximilian N.
581 Diefenbach, Gerhard Dobler, Jürgen Durner, Judith Eckstein, Philine Falk, Volker
582 Fingerle, Felix Forster, Turid Frahnöw, Guenter Froeschl, Otto Geisenberger,
583 Kristina Gillig, Philipp Girl, Pablo Gutierrez, Anselm Haderer, Marlene Hannes, Jan
584 Hasenauer, Tim Haselwarter, Alejandra Hernandez, Matthias Herrmann, Leah Hillari,
585 Christian Hinske, Tim Hofberger, Sacha Horn, Kristina Huber, Christian Janke,
586 Ursula Kappl, Antonia Kessler, Zohaib N. Khan, Johanna Kresin, Arne Kroidl,
587 Magdalena Lang, Silvan Lange, Michael Laxy, Ronan Le Gleut, Reiner Leidl,
588 Leopold Liedl, Xhovana Lucaj, Petra Mang, Alisa Markgraf, Rebecca Mayrhofer,
589 Dafni Metaxa, Hannah Mueller, Katharina Mueller, Laura Olbrich, Ivana Paunovic,
590 Claire Pleimelding, Michel Pletschette, Stephan Prueckner, Kerstin Puchinger, Peter

591 Puetz, Katja Radon, Elba Raimundéz, Jakob Reich, Friedrich Riess, Camilla Rothe,
592 Viktoria Ruci, Nicole Schaefer, Yannik Schaelte, Benedikt Schluse, Elmar Saathoff,
593 Lara Schneider, Mirjam Schunk, Lars Schwettmann, Peter Sothmann, Kathrin Strobl,
594 Jeni Tang, Fabian Theis, Verena Thiel, Jonathan von Lovenberg, Julia Waibel,
595 Claudia Wallrauch, Roman Woelfel, Julia Wolff, Tobias Wuerfel, Sabine Zange,
596 Eleftheria Zeggini, Anna Zielke.

597

598

599 References

- 600 1. Clark D V, Kibuuka H, Millard M, et al. Long-term sequelae after Ebola virus
601 disease in Bundibugyo, Uganda: a retrospective cohort study. *Lancet Infect*
602 *Dis.* 2015;15(8):905-912. doi:10.1016/S1473-3099(15)70152-0
- 603 2. A Post-Graduate Lecture ON THE NERVOUS SEQUELÆ OF INFLUENZA.
604 *Lancet.* 1893;142(3645):73-76. doi:[https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(00)65088-2)
605 [6736\(00\)65088-2](https://doi.org/10.1016/S0140-6736(00)65088-2)
- 606 3. Fluge Ø, Tronstad KJ, Mella O. Pathomechanisms and possible interventions
607 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *J Clin*
608 *Invest.* 2021;131(14). doi:10.1172/JCI1150377
- 609 4. Newton DJ, Kennedy G, Chan KKF, Lang CC, Belch JJF, Khan F. Large and
610 small artery endothelial dysfunction in chronic fatigue syndrome. *Int J Cardiol.*
611 2012;154(3):335-336. doi:10.1016/j.ijcard.2011.10.030
- 612 5. Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the
613 Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute
614 Infection and Public Health Implications. *JAMA.* 2020;324(22):2251-2252.
615 doi:10.1001/jama.2020.22717
- 616 6. Sivan M, Taylor S. NICE guideline on long covid. *BMJ.* 2020;371:m4938.
617 doi:10.1136/bmj.m4938
- 618 7. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms,
619 risk factors, and management. *BMJ.* 2021;374:n1648. doi:10.1136/bmj.n1648
- 620 8. Margalit I, Yelin D, Sagi M, et al. Risk Factors and Multidimensional
621 Assessment of Long Coronavirus Disease Fatigue: A Nested Case-Control
622 Study. *Clin Infect Dis.* 2022;75(10):1688-1697. doi:10.1093/cid/ciac283
- 623 9. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection
624 syndromes. *Nat Med.* 2022;28(5):911-923. doi:10.1038/s41591-022-01810-6
- 625 10. Kreutmair S, Unger S, Núñez NG, et al. Distinct immunological signatures
626 discriminate severe COVID-19 from non-SARS-CoV-2-driven critical
627 pneumonia. *Immunity.* 2021;54(7):1578-1593.e5.
628 doi:10.1016/j.immuni.2021.05.002
- 629 11. Bergamaschi L, Mescia F, Turner L, et al. Longitudinal analysis reveals that

- 630 delayed bystander CD8+ T cell activation and early immune pathology
631 distinguish severe COVID-19 from mild disease. *Immunity*. 2021;54(6):1257-
632 1275.e8. doi:10.1016/j.immuni.2021.05.010
- 633 12. Blot M, Bour J-B, Quenot JP, et al. The dysregulated innate immune response
634 in severe COVID-19 pneumonia that could drive poorer outcome. *J Transl*
635 *Med*. 2020;18(1):457. doi:10.1186/s12967-020-02646-9
- 636 13. Lim J, Puan KJ, Wang LW, et al. Data-Driven Analysis of COVID-19 Reveals
637 Persistent Immune Abnormalities in Convalescent Severe Individuals . *Front*
638 *Immunol* . 2021;12.
639 <https://www.frontiersin.org/articles/10.3389/fimmu.2021.710217>
- 640 14. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and
641 endotheliitis in COVID-19. *Lancet*. 2020;395(10234):1417-1418.
642 doi:10.1016/S0140-6736(20)30937-5
- 643 15. Cheon IS, Li C, Son YM, et al. Immune signatures underlying post-acute
644 COVID-19 lung sequelae. *Sci Immunol*. 2022;6(65):eabk1741.
645 doi:10.1126/sciimmunol.abk1741
- 646 16. Klein J, Wood J, Jaycox J, et al. Distinguishing features of Long COVID
647 identified through immune profiling. *medRxiv*. Published online January
648 2022:2022.08.09.22278592. doi:10.1101/2022.08.09.22278592
- 649 17. Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction
650 persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection.
651 *Nat Immunol*. 2022;23(2):210-216. doi:10.1038/s41590-021-01113-x
- 652 18. Moro K, Yamada T, Tanabe M, et al. Innate production of TH2 cytokines by
653 adipose tissue-associated c-Kit+Sca-1+ lymphoid cells. *Nature*.
654 2010;463(7280):540-544. doi:10.1038/nature08636
- 655 19. Vivier E, Artis D, Colonna M, et al. Innate Lymphoid Cells: 10 Years On. *Cell*.
656 2018;174(5):1054-1066. doi:10.1016/j.cell.2018.07.017
- 657 20. Cautivo KM, Matatia PR, Lizama CO, et al. Interferon gamma constrains type
658 2 lymphocyte niche boundaries during mixed inflammation. *Immunity*.
659 2022;55(2):254-271.e7. doi:10.1016/j.immuni.2021.12.014
- 660 21. Dahlgren MW, Molofsky AB. All along the watchtower: group 2 innate lymphoid
661 cells in allergic responses. *Curr Opin Immunol*. 2018;54:13-19.
- 662 22. Gomez-Cadena A, Spehner L, Kroemer M, et al. Severe COVID-19 patients
663 exhibit an ILC2 NKG2D+ population in their impaired ILC compartment. *Cell*
664 *Mol Immunol*. 2021;18(2):484-486. doi:10.1038/s41423-020-00596-2
- 665 23. Silverstein NJ, Wang Y, Manickas-Hill Z, et al. Innate lymphoid cells and
666 COVID-19 severity in SARS-CoV-2 infection. Giamarellos-Bourboulis EJ, Rath
667 S, Giamarellos-Bourboulis EJ, Kyriazopoulou E, eds. *Elife*. 2022;11:e74681.
668 doi:10.7554/eLife.74681
- 669 24. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of
670 post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom
671 Study app: a prospective, community-based, nested, case-control study.
672 *Lancet Infect Dis*. 2022;22(1):43-55. doi:10.1016/S1473-3099(21)00460-6


- 673 25. Magnusson K, Kristoffersen DT, Dell'Isola A, et al. Post-covid medical
674 complaints following infection with SARS-CoV-2 Omicron vs Delta variants.
675 *Nat Commun.* 2022;13(1):7363. doi:10.1038/s41467-022-35240-2
- 676 26. Kaiser R, Leunig A, Pekayvaz K, et al. Self-sustaining IL-8 loops drive a
677 prothrombotic neutrophil phenotype in severe COVID-19. *JCI Insight.*
678 2021;6(18). doi:10.1172/jci.insight.150862
- 679 27. Zhang Z, Ai G, Chen L, et al. Associations of immunological features with
680 COVID-19 severity: a systematic review and meta-analysis. *BMC Infect Dis.*
681 2021;21(1):738. doi:10.1186/s12879-021-06457-1
- 682 28. Sabbatino F, Conti V, Franci G, et al. PD-L1 Dysregulation in COVID-19
683 Patients . *Front Immunol* . 2021;12.
684 <https://www.frontiersin.org/articles/10.3389/fimmu.2021.695242>
- 685 29. Mazzurana L, Bonfiglio F, Forkel M, D'Amato M, Halfvarson J, Mjösberg J.
686 Crohn's Disease Is Associated With Activation of Circulating Innate Lymphoid
687 Cells. *Inflamm Bowel Dis.* 2021;27(7):1128-1138. doi:10.1093/ibd/izaa316
- 688 30. Lim AI, Li Y, Lopez-Lastra S, et al. Systemic Human ILC Precursors Provide a
689 Substrate for Tissue ILC Differentiation. *Cell.* 2017;168(6):1086-1100.e10.
690 doi:10.1016/j.cell.2017.02.021
- 691 31. Kokkinou E, Pandey RV, Mazzurana L, et al. CD45RA+CD62L- ILCs in
692 human tissues represent a quiescent local reservoir for the generation of
693 differentiated ILCs. *Sci Immunol.* 2023;7(70):eabj8301.
694 doi:10.1126/sciimmunol.abj8301
- 695 32. Fonseca W, Lukacs NW, Elesela S, Malinczak C-A. Role of ILC2 in Viral-
696 Induced Lung Pathogenesis . *Front Immunol* . 2021;12.
- 697 33. Vanoni G, Ercolano G, Candiani S, et al. Human primed ILCPs support
698 endothelial activation through NF-κB signaling. Cerullo V, Taniguchi T, eds.
699 *Elife.* 2021;10:e58838. doi:10.7554/eLife.58838
- 700 34. Brand I, Gilberg L, Bruger J, et al. Broad T Cell Targeting of Structural Proteins
701 After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity
702 Using an Automated Interferon Gamma Release Assay . *Front Immunol* .
703 2021;12.
- 704 35. Pritsch M, Radon K, Bakuli A, et al. Prevalence and Risk Factors of Infection in
705 the Representative COVID-19 Cohort Munich. *Int J Environ Res Public Health.*
706 2021;18(7). doi:10.3390/ijerph18073572
- 707 36. Kotecha N, Krutzik PO, Irish JM. Web-based analysis and publication of flow
708 cytometry experiments. *Curr Protoc Cytom.* 2010;Chapter 10:Unit10.17-
709 Unit10.17. doi:10.1002/0471142956.cy1017s53
- 710 37. Rogers WT, Holyst HA. FlowFP: A Bioconductor Package for Fingerprinting
711 Flow Cytometric Data. Gottardo R, ed. *Adv Bioinformatics.* 2009;2009:193947.
712 doi:10.1155/2009/193947

713


714

Figure 1

A




B




C

Acute Covid severity



D



E





Figure 2

Table 1. Clinical characteristics of patient cohorts

	Healthy Controls (HC)	Convalescent Controls (CC)	Post Covid (PC)
n	32	32	27
Sex			
Male	15 (46.9%)	14 (43.8%)	9 (33.3%)
Female	17 (53.1%)	18 (56.2%)	18 (66.7%)
Age (years)			
20-29	6 (18.8%)	6 (18.8%)	4 (14.8%)
30-39	10 (31.2%)	12 (37.5%)	10 (37.0%)
40-49	15 (46.9%)	12 (37.5%)	8 (29.6%)
>49	1 (3.1%)	2 (6.2%)	5 (18.5%)
Mean	36	36	37
BMI (kg/m ²)			
<18,5	3 (9.4%)	0 (0%)	0 (0%)
18,5-25	14 (43.8%)	22 (68.8%)	15 (55.6%)
25-30	10 (31.2%)	9 (28.1%)	4 (14.8%)
>30	5 (13.6%)	1 (3.1%)	3 (11.1%)
Mean	25.2	23.4	24
Time from PCR to visit median (in days)		273 (Min:125; Max: 318)	113 (Min: 89; Max: 292)

Data are given as numbers (percentages). BMI, body mass index.

Sex, age and BMI were comparable between groups with an overall mean age of 36 years, 58% females and BMI of 24.2kg/m²